Rhenman & Partners Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.55M	Sell	92,605 -13,650	-13%	-$1.28M	1.06%	38
2025 Q4	$8.39M	Buy	106,255 +50,000	+89%	+$3.59M	0.78%	51
2025 Q3	$4.12M	Sell	56,255 -9,500	-14%	-$604K	0.46%	62
2025 Q2	$3.35M	Sell	65,755 -8,000	-11%	-$356K	0.42%	62
2025 Q1	$3.32M	Hold	73,755	–	–	0.38%	56
2024 Q4	$3.05M	Sell	73,755 -31,245	-30%	-$1.3M	0.31%	69
2024 Q3	$4.09M	Sell	105,000 -29,250	-22%	-$1.17M	0.33%	70
2024 Q2	$4.59M	Buy	134,250 +42,000	+46%	+$1.1M	0.44%	57
2024 Q1	$2.32M	Buy	+92,250	New	+$2.54M	0.22%	72

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Rhenman & Partners Asset Management's MIRM Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Mirum Pharmaceuticals (MIRM) stake by 13% in Q1 2026, selling an estimated $1.28M and leaving 92,605 shares worth $8.55M. The position accounts for 1.06% of the portfolio, ranked #38.

Rhenman & Partners Asset Management first reported a position in MIRM in Q1 2024 and has held it in 9 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Rhenman & Partners Asset Management held 92,605 shares of Mirum Pharmaceuticals worth $8.55M as of Q1 2026.
Rhenman & Partners Asset Management sold 13,650 Mirum Pharmaceuticals shares in Q1 2026, an estimated $1.28M.
Mirum Pharmaceuticals made up 1.06% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #38 holding.
Rhenman & Partners Asset Management first reported a position in Mirum Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.